Elevation Oncology (ELEV)
(Delayed Data from NSDQ)
$3.61 USD
0.00 (0.00%)
Updated May 17, 2024 04:00 PM ET
After-Market: $3.63 +0.02 (0.55%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Elevation Oncology, Inc. [ELEV]
Reports for Purchase
Showing records 21 - 40 ( 51 total )
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
EO-3021 Oral Presentation at AACR; Partial Response in GI Cancer Case Study
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
The Case for Claudin Strengthens; EO-3021 Stands to Benefit
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; EO-3021 Ph 1 on Track to Initiate in Busy Claudin18.2 Landscape
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Ph 2 CRESTONE Interim Data in 1H:23; EO-321 Initiation in 2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Deeper Look at Seribantumab Responses Could Set Up Next Loxo/Ignyta; Assuming Coverage With Buy Rating and $7.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Pipeline Expansion Sets up a Busy Year Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Expanding Pipeline with Ph 1 anti-Claudin18.2 ADC from CSPC
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Promising Initial Look at Seribantumab in CRESTONE; First Complete Responses
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R